1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Indiana >
  6. Immunome Acquires MorphImmune

M&A Deal Summary

Immunome Acquires MorphImmune

On June 29, 2023, Immunome acquired life science company MorphImmune

Acquisition Highlights
  • This is Immunome’s 1st transaction in the Life Science sector.
  • This is Immunome’s 1st transaction in the United States.
  • This is Immunome’s 1st transaction in Indiana.

M&A Deal Summary
Date 2023-06-29
Target MorphImmune
Sector Life Science
Buyer(s) Immunome
Deal Type Merger
Advisor(s) Cooley (Legal)

Target

MorphImmune

West Lafayette, Indiana, United States
Morphimmune is a biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases the efficacy of known effector molecules, ultimately improving outcomes for patients. Morphimmune is based in West Lafayette, Indiana.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Immunome

Bothell, Washington, United States
Category Company
Founded 2006
Sector Life Science
Employees131
Revenue 9M USD (2024)
DESCRIPTION

Immunome is a biopharmaceutical company utilizing its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Immunome was founded in 2006 and is based in Bothell, Washington.

DEAL STATS #
Overall 1 of 3
Sector: Life Science M&A 1 of 3
Type: Merger M&A Deals 1 of 1
State: Indiana M&A 1 of 1
Country: United States M&A 1 of 3
Year: 2023 M&A 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-26 Atreca - Antibody s Related Assets and Materials

United States

Atreca's Antibody's Related Assets and Materials are complementing the mission of developing innovative treatments for cancer patients.

Buy $6M
Mergr

Solution for

Product

Company

Legal